| Q87936775 | 18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center |
| Q42926785 | A case of cardiac herniation after extrapleural pneumonectomy for malignant thymoma |
| Q39434224 | A nuanced view of extrapleural pneumonectomy for malignant pleural mesothelioma |
| Q59132458 | A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205) |
| Q36948470 | Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma |
| Q35832903 | Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach |
| Q38153818 | Advances in the management of pleural disease. |
| Q30478994 | BTS statement on malignant mesothelioma in the UK, 2007. |
| Q58693283 | Blood Loss and Massive Transfusion in Patients Undergoing Major Oncological Surgery: What Do We Know? |
| Q38083599 | Changes in lung function after surgery for mesothelioma |
| Q86113339 | Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens |
| Q40688498 | Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. |
| Q38756416 | Consensus statement: Using laryngeal electromyography for the diagnosis and treatment of vocal cord paralysis |
| Q38641574 | Current surgical strategies for malignant pleural mesothelioma |
| Q34248396 | Diaphragmatic Herniation through Prosthetic Material after Extrapleural Pneumonectomy: Be Aware of Tumor Recurrence |
| Q55014231 | Diaphragmatic and pericardial reconstruction after surgery for malignant pleural mesothelioma. |
| Q85089512 | Early Unilateral Laryngeal Paralysis After Pulmonary Resection With Mediastinal Dissection for Cancer |
| Q83206656 | Early mesothelioma revisited |
| Q58853910 | Effects of pneumonectomy on nitric oxide synthase expression and perivascular edema in the remaining lung of rats |
| Q64080942 | Extra-pleural pneumonectomy |
| Q35141809 | Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study |
| Q33871592 | Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D). |
| Q38935100 | Extrapleural pneumonectomy for malignant pleural mesothelioma: is this an operation that should now be consigned to history? |
| Q51111506 | Extrapleural pneumonectomy via a lower door open thoracotomy with reconstruction of the diaphragm and pericardium using autologous materials for mesothelioma. |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q35699080 | Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma |
| Q46397837 | Global incidence and case fatality rate of pulmonary embolism following major surgery: a protocol for a systematic review and meta-analysis of cohort studies. |
| Q92969758 | Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma |
| Q33400437 | Induction chemotherapy, extrapleural pneumonectomy, and adjuvant radiotherapy for malignant pleural mesothelioma: experience of Guy's and St Thomas' hospitals |
| Q37130217 | Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma |
| Q35960207 | Innovative therapies: intraoperative intracavitary chemotherapy |
| Q34293068 | Investigational approaches for mesothelioma |
| Q47133919 | Laparoscopic repair of a peritoneopericardial diaphragmatic hernia after a convergent procedure for the treatment of atrial fibrillation |
| Q38255347 | Local and systemic therapies for malignant pleural mesothelioma |
| Q51589436 | Long-term outcome of pleuropneumonectomy for Masaoka stage IVa thymoma. |
| Q34616102 | Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. |
| Q37613240 | Making the case for molecular staging of malignant pleural mesothelioma |
| Q21202901 | Malignant mesothelioma |
| Q80961479 | Malignant mesothelioma |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q37209613 | Malignant mesothelioma: current status and perspective in Japan and the world |
| Q83412919 | Malignant pleural mesothelioma |
| Q84107270 | Malignant pleural mesothelioma |
| Q37529848 | Malignant pleural mesothelioma: current treatments and emerging drugs. |
| Q38443843 | Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital |
| Q38215513 | Management of malignant pleural mesothelioma-The European experience |
| Q37277434 | Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). |
| Q36830116 | Management options for malignant pleural mesothelioma: clinical and cost considerations |
| Q36599666 | Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent? |
| Q86628564 | Multimodal treatment for malignant pleural mesothelioma |
| Q36157300 | New therapeutic options for mesothelioma |
| Q33871599 | Overview of treatment related complications in malignant pleural mesothelioma |
| Q35210613 | Photodynamic therapy in the management of malignant pleural mesothelioma: A review |
| Q35903121 | Pleural mesothelioma: little evidence, still time to do trials |
| Q37089137 | Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience |
| Q44986726 | Postoperative ambulation in thoracic surgery patients: standard versus modern ambulation methods |
| Q97538980 | Postoperative atrial fibrillation prophylaxis using a novel amiodarone order set |
| Q39079691 | Postoperative morbidity and mortality after pneumonectomy: a 30-year experience of 2064 consecutive patients |
| Q84790766 | Predictors of Major Morbidity and Mortality After Pneumonectomy Utilizing The Society for Thoracic Surgeons General Thoracic Surgery Database |
| Q35867302 | Preliminary results of tomotherapy for treatment of inoperable recurrent non-small cell lung cancer at bronchial stump site after right pneumonectomy |
| Q24632902 | Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q24187077 | Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery |
| Q24203816 | Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery |
| Q64234040 | Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma |
| Q41368043 | Properties of novel composite meshes in chest wall reconstruction: A comparative animal study |
| Q37090803 | Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? |
| Q89955245 | Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma |
| Q42283157 | Salvage therapy with topical antifungal for Aspergillus fumigatus empyema complicating extrapleural pneumonectomy |
| Q37762833 | Surgery for malignant pleural mesothelioma |
| Q42552039 | Technical pitfalls and solutions in extrapleural pneumonectomy. |
| Q35200628 | The role of interleukin-6 in malignant mesothelioma |
| Q36581575 | Thoracic wall reconstruction with Collamend® in trauma: report of a case and review of the literature |
| Q41885544 | Thoracoscopic management of empyema thoracis |
| Q40341641 | Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma. |
| Q61583558 | Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future |
| Q36067869 | Use of postoperative creatinine to predict sustained kidney injury in patients undergoing mesothelioma surgery |
| Q35660608 | Using clinical parameters to guide fluid therapy in high-risk thoracic surgery. A retrospective, observational study |
| Q87357879 | WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience |
| Q36097571 | What is the optimum strategy for thromboembolic prophylaxis following extrapleural pneumonectomy in patients with malignant pleural mesothelioma? |
| Q83277189 | ["Therapeutic" pleural surgery] |
| Q82061962 | [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma] |
| Q86613725 | [Intraoperative chemotherapy after radical pleurectomy or extrapleural pneumonectomy] |
| Q80426618 | [Malignant pleural mesothelioma: interrogations and hopes concerning the expected epidemic] |
| Q86911325 | [Regional treatment of malignant pleural mesothelioma: results from the tumor centre Regensburg] |
| Q84559858 | [Thoracic surgery: the major surgical procedures] |